Standard of Care for Soft-Tissue Sarcoma

Submitted by admin5 on Thu, 10/26/2017 - 04:09

According to a recent study published in The LANCET Oncology, which treatment option is considered and should remain the standard of care for soft-tissue sarcoma?


A. Gemcitabine

B. Doxorubicin

C. Eribulin 

D. Gemcitabine plus doxorubicin 


To see the correct answer, click here.


Related Content

Soft Tissue Sarcoma Differences Might Have Therapeutic Implications

Survivors of Soft-Tissue Sarcoma Face Increased Risk of Hospitalization